Report overview
This report contains market size and forecasts of Cancer Angiogenesis Inhibitors in global, including the following market information:
Global Cancer Angiogenesis Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cancer Angiogenesis Inhibitors Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Cancer Angiogenesis Inhibitors companies in 2021 (%)
The global Cancer Angiogenesis Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
VEGF Targeted Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cancer Angiogenesis Inhibitors include Intas Pharmaceuticals, Kyowa Hakko Kirin, Levolta Pharmaceuticals, Mabtech, Marsala Biotech, Neumedicines, Genentech, Five Prime Therapeutics and Fuji Film Kyowa Kirin Biologics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Angiogenesis Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Angiogenesis Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Angiogenesis Inhibitors Market Segment Percentages, by Type, 2021 (%)
VEGF Targeted Therapy
FGF Targeted Therapies
Oncogene Targeted Therapy
Matrix Degrading & Remodeling Targeted Therapy
Others
Global Cancer Angiogenesis Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Angiogenesis Inhibitors Market Segment Percentages, by Application, 2021 (%)
Cancer
Interferon Alpha-2?
Ocular Neovascularization
Global Cancer Angiogenesis Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Angiogenesis Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Angiogenesis Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cancer Angiogenesis Inhibitors revenues share in global market, 2021 (%)
Key companies Cancer Angiogenesis Inhibitors sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Cancer Angiogenesis Inhibitors sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Intas Pharmaceuticals
Kyowa Hakko Kirin
Levolta Pharmaceuticals
Mabtech
Marsala Biotech
Neumedicines
Genentech
Five Prime Therapeutics
Fuji Film Kyowa Kirin Biologics
Genexine
Hetero Drugs
ImClone Systems
Novartis
